ReviewRevista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia2018
[Phage therapy, an alternative to antibiotic therapy?)].
Review in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular mechanisms of multidrug resistance in clinically relevant enteropathogenic bacteria (Review).Experimental and therapeutic medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriophages are viruses that infect and parasitize bacteria. They can present a lytic cycle that determines the lysis of the infected bacteria. Each phage is specific to a particular bacterial genus or species. The current increase in the incidence of antibiotic resistance in human bacteria has favored the study of phages as a therapeutic alternative (phage therapy). Previous studies have shown the efficacy of these elements in cutaneous and intestinal infections. Different clinical trials are underway to establish the safety, reactogenicity and therapeutic efficacy of multiple phage. Being active elements, phages must undergo rigorous quality controls to ensure the absence of undesirable effects. The bacterial lysis that they cause is of a magnitude inferior to the one provoked by the antibiotics. As problems to be solved in the future are the possibility of using mixtures of several phages, establish the ideal route of administration and modify them genetically to deactivate bacterial resistance genes.
Indexed as
Identifiers
29451376PMC6159377What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.